510(k) device
MamaLift Plus
Curio Digital Therapeutics, Inc. · Computerized Behavioral Therapy Device For Depressive Disorders. (SAP, Class II) · First FDA decision Apr 22, 2024, newest Apr 22, 2024Depression
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
1
Naming "MamaLift Plus"
MAUDE reports
0
Brand "MamaLift Plus", since 2015
PubMed studies
1
Mentioning "MamaLift Plus"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing MamaLift Plus
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- MamaLift Plus510(k)
K223515 · Decided Apr 22, 2024 · 517 days after receipt
Device type: Computerized Behavioral Therapy Device For Depressive Disorders. (SAP) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Intensive Behavioral Therapy for ObesityNational analysisReview closedCAG-00423NUpdated Sep 18, 2026
- Intensive Behavioral Therapy for Cardiovascular DiseaseNational analysisReview closedCAG-00424NUpdated Sep 18, 2026
- Intensive Behavioral Therapy for ObesityNational determinationOn the books210.12Updated Dec 2, 2024
- Intensive Behavioral Therapy for Cardiovascular DiseaseNational determinationOn the books210.11Updated Dec 2, 2024
- Fluidized Therapy Dry Heat for Certain Musculoskeletal DisordersNational determinationOn the books150.8Updated Apr 17, 2020
- Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive DisorderLocal determinationIn effectL34522First Coast Service Options, Inc.Updated Oct 21, 2022
- Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive DisorderLocal determinationIn effectL34998Novitas Solutions, Inc.Updated Oct 21, 2022
Clinical trials
Device studies on ClinicalTrials.gov that name "MamaLift Plus", any status and sponsor, newest update first.
- Curio Digital Therapy for the Treatment of Post-partum DepressionPivotal-lookingStatus unknown
Healthcare Innovation Technology LabNot on our public-company list
NCT05958095 · 142 participants · Start Apr 1, 2023 · Primary completion May 24, 2023
Device: MamaLift Plus; Digital Sham App · For: PostPartum Depression
Sites: New York, New York
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "MamaLift Plus", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SAP
1 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "MamaLift Plus"[tiab]. The summary above synthesizes these.
- Evaluating the Efficacy of MamaLift Plus Digital Therapeutic Mobile App for Postpartum Depression (SuMMER): Randomized, Placebo-Controlled Pivotal Trial.
Dixit S, Malladi I, Shankar S, et al. · J Med Internet Res · 2025Randomized Controlled Trial, Clinical Trial, Phase III
Other devices of this type
Also filed under product code SAP.
- Motivista (CT-155)Click Therapeutics, Inc. · 510(k) 2026
- RejoynOtsuka America Pharmaceutical, Inc. · 510(k) 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.